Pharmacological Treatment for Alcoholism

National Institute on Alcohol Abuse and Alcoholism (NIAAA)1 site in 1 countryNovember 3, 1999

ConditionsAlcoholism

Drugsondansetron (Zofran)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Alcoholism
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Locations: 1
Status: Completed
Last Updated: 20 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.

Registry

clinicaltrials.gov

Start Date

November 3, 1999

End Date

April 2000

Last Updated

20 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Eligibility Criteria

Inclusion Criteria

•Meet criteria for alcohol dependence.
•Subjects with early onset alcoholism must also have a diagnosis of antisocial personality disorder.
•Understand the requirements of the study and be able to complete the questionnaires and rating scales.

Exclusion Criteria

•Current diagnosis of substance dependence or self-report of having used narcotics (opiates, cocaine, amphetamine-like substances, and hallucinogens) in the 30 day period prior to study.
•Positive urine drug screen test for narcotics, barbiturates, or benzodiazepines.
•Receiving current psychotropic medications.
•Current history of other psychiatric disorders excluding nicotine dependence.
•Hepatocellular disease.
•Pregnant females.